Zipalertinib efficacy data in NSCLC patients to be presented at IASLC 2025 World Conference.

Taiho Oncology and Cullinan Therapeutics will present new data from the REZILIENT1 and REZILIENT2 trials at the 2025 World Conference on Lung Cancer. The presentations will include updated efficacy and safety data from the Phase 2b REZILIENT1 trial for patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations, and preliminary findings from the cohort of patients with uncommon non-ex20ins EGFR mutations enrolled in the REZILIENT2 trial.

Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., have announced the acceptance of abstracts for presentation at the International Association of the Study of Lung Cancer's (IASLC) 2025 World Conference on Lung Cancer (WCLC), to be held September 6-9, 2025, in Barcelona, Spain. The presentations will feature new data from the REZILIENT1 and REZILIENT2 trials of zipalertinib, an orally available small molecule designed to target activating mutations in EGFR.

The abstracts accepted for mini oral presentations include updated efficacy and safety data from the Phase 2b REZILIENT1 trial, focusing on patients with EGFR exon 20 insertion mutations (ex20ins) who were previously treated with amivantamab. Additionally, the presentations will include preliminary efficacy and safety results from the Phase 2 parallel cohort REZILIENT2 trial in patients with advanced or metastatic NSCLC harboring uncommon non-ex20ins EGFR mutations [1].

Harold Keer, MD, PhD, Chief Medical Officer at Taiho Oncology, commented, "Previously, zipalertinib has demonstrated clinical activity against ex20ins and preclinical activity against uncommon, non-ex20ins EGFR-mutant NSCLC. We look forward to sharing updated data from the REZILIENT1 and REZILIENT2 trials at the upcoming 2025 World Conference on Lung Cancer, suggesting the potential for zipalertinib to make a meaningful difference in the lives of patients with certain types of NSCLC."

Jeffrey Jones, MD, MBA, Chief Medical Officer at Cullinan Therapeutics, added, "Despite advances in the treatment landscape, there remains significant unmet need for NSCLC patients with EGFR exon 20 insertion mutations and for those with uncommon non-ex20ins EGFR mutations. Taken together, the updated results from REZILIENT1 and new data from the REZILIENT2 study highlight the potential of zipalertinib to play an important role in the evolving treatment landscape for patients with NSCLC harboring less common EGFR mutations."

The presentations will take place on Tuesday, September 9, 2025, from 11:30 a.m. to 12:45 p.m. CEST. Full abstract details will be available via the conference website at 1 p.m. EDT August 13, 2025 [1].

References:

[1] https://www.prnewswire.com/news-releases/taiho-oncology-and-cullinan-therapeutics-announce-acceptance-of-abstracts-for-zipalertinib-at-the-iaslc-2025-world-conference-on-lung-cancer-302510269.html